Short-term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis
ObjectiveTo determine the short-term effectiveness safety of baricitinib in children with refractory and/or severe juvenile dermatomyositis (rsJDM) in a real-world setting.MethodsThis was a single-center retrospective study, including 20 children with rsJDM. They were all treated using baricitinib c...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Pediatrics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fped.2022.962585/full |
| _version_ | 1828147759561048064 |
|---|---|
| author | Zhaoling Wang Qi Zheng Wenjie Xuan Xisheng Xu Meiping Lu Jianqiang Wu Lixia Zou Yiping Xu Xuefeng Xu |
| author_facet | Zhaoling Wang Qi Zheng Wenjie Xuan Xisheng Xu Meiping Lu Jianqiang Wu Lixia Zou Yiping Xu Xuefeng Xu |
| author_sort | Zhaoling Wang |
| collection | DOAJ |
| description | ObjectiveTo determine the short-term effectiveness safety of baricitinib in children with refractory and/or severe juvenile dermatomyositis (rsJDM) in a real-world setting.MethodsThis was a single-center retrospective study, including 20 children with rsJDM. They were all treated using baricitinib combined with steroids and other immunosuppressive agents. The childhood myositis assessment scale (CMAS) and PRINTO remission criteria were used to evaluate the disease severity and treatment outcome at 0, 4, 12, and 24 weeks after initiation of baricitinib.ResultsThe skin rash improved in 95% of patients (19/20) at week 24, with a significant decrease of skin-DAS at weeks 12 (6.0 vs. 2.0, p < 0.05] and week 24 [6.0 vs. 1.0, p < 0.05) by median statistics. The CMAS score increased significantly at week 12 (41.0 [29.0, 44.0] vs. 46.0 [42.0, 52.0], p < 0.05) and week 24 (41.0 [29.0, 44.0] vs. 50.0 [45.0, 52.0], p < 0.05), as did the manual muscle testing (MMT)-8 score at week 24 (73.0 [610, 76.0] vs. 79.0 [77.0, 80.0], p < 0.05). At 24 weeks, the complete response (CR) and partial response (PR) were achieved in 75% (15/20) and 15% (3/20), respectively. The dose of corticosteroids (CS) decreased by 37% from the baseline (0.53 [0.42, 1.00] mg/kg) to week 12 (0.33 [0.18, 0.40] mg/kg) (p < 0.05), and by 49% at week 24 (p < 0.05). No serious side effects were observed.ConclusionBaricitinib combined with traditional immunosuppressants treatment was efficacious in rsJDM. Add-on therapy of baricitinib was helpful for tapering CS dose. No serious side effects were observed in this study. |
| first_indexed | 2024-04-11T21:04:53Z |
| format | Article |
| id | doaj.art-68a9c32f89b9424f9cd5a851d9f98a1e |
| institution | Directory Open Access Journal |
| issn | 2296-2360 |
| language | English |
| last_indexed | 2024-04-11T21:04:53Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pediatrics |
| spelling | doaj.art-68a9c32f89b9424f9cd5a851d9f98a1e2022-12-22T04:03:23ZengFrontiers Media S.A.Frontiers in Pediatrics2296-23602022-09-011010.3389/fped.2022.962585962585Short-term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositisZhaoling Wang0Qi Zheng1Wenjie Xuan2Xisheng Xu3Meiping Lu4Jianqiang Wu5Lixia Zou6Yiping Xu7Xuefeng Xu8Department of Rheumatology Immunology and Allergy, Children’s Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, ChinaDepartment of Rheumatology Immunology and Allergy, Children’s Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, ChinaDepartment of Pediatric, Shaoxing People’s Hospital, Shaoxing, ChinaDepartment of Rheumatology Immunology and Allergy, Children’s Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, ChinaDepartment of Rheumatology Immunology and Allergy, Children’s Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, ChinaDepartment of Rheumatology Immunology and Allergy, Children’s Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, ChinaDepartment of Rheumatology Immunology and Allergy, Children’s Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, ChinaDepartment of Rheumatology Immunology and Allergy, Children’s Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, ChinaDepartment of Rheumatology Immunology and Allergy, Children’s Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, ChinaObjectiveTo determine the short-term effectiveness safety of baricitinib in children with refractory and/or severe juvenile dermatomyositis (rsJDM) in a real-world setting.MethodsThis was a single-center retrospective study, including 20 children with rsJDM. They were all treated using baricitinib combined with steroids and other immunosuppressive agents. The childhood myositis assessment scale (CMAS) and PRINTO remission criteria were used to evaluate the disease severity and treatment outcome at 0, 4, 12, and 24 weeks after initiation of baricitinib.ResultsThe skin rash improved in 95% of patients (19/20) at week 24, with a significant decrease of skin-DAS at weeks 12 (6.0 vs. 2.0, p < 0.05] and week 24 [6.0 vs. 1.0, p < 0.05) by median statistics. The CMAS score increased significantly at week 12 (41.0 [29.0, 44.0] vs. 46.0 [42.0, 52.0], p < 0.05) and week 24 (41.0 [29.0, 44.0] vs. 50.0 [45.0, 52.0], p < 0.05), as did the manual muscle testing (MMT)-8 score at week 24 (73.0 [610, 76.0] vs. 79.0 [77.0, 80.0], p < 0.05). At 24 weeks, the complete response (CR) and partial response (PR) were achieved in 75% (15/20) and 15% (3/20), respectively. The dose of corticosteroids (CS) decreased by 37% from the baseline (0.53 [0.42, 1.00] mg/kg) to week 12 (0.33 [0.18, 0.40] mg/kg) (p < 0.05), and by 49% at week 24 (p < 0.05). No serious side effects were observed.ConclusionBaricitinib combined with traditional immunosuppressants treatment was efficacious in rsJDM. Add-on therapy of baricitinib was helpful for tapering CS dose. No serious side effects were observed in this study.https://www.frontiersin.org/articles/10.3389/fped.2022.962585/fullbaricitinibjuvenile dermatomyositisrefractoryseveretreatment |
| spellingShingle | Zhaoling Wang Qi Zheng Wenjie Xuan Xisheng Xu Meiping Lu Jianqiang Wu Lixia Zou Yiping Xu Xuefeng Xu Short-term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis Frontiers in Pediatrics baricitinib juvenile dermatomyositis refractory severe treatment |
| title | Short-term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis |
| title_full | Short-term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis |
| title_fullStr | Short-term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis |
| title_full_unstemmed | Short-term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis |
| title_short | Short-term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis |
| title_sort | short term effectiveness of baricitinib in children with refractory and or severe juvenile dermatomyositis |
| topic | baricitinib juvenile dermatomyositis refractory severe treatment |
| url | https://www.frontiersin.org/articles/10.3389/fped.2022.962585/full |
| work_keys_str_mv | AT zhaolingwang shorttermeffectivenessofbaricitinibinchildrenwithrefractoryandorseverejuveniledermatomyositis AT qizheng shorttermeffectivenessofbaricitinibinchildrenwithrefractoryandorseverejuveniledermatomyositis AT wenjiexuan shorttermeffectivenessofbaricitinibinchildrenwithrefractoryandorseverejuveniledermatomyositis AT xishengxu shorttermeffectivenessofbaricitinibinchildrenwithrefractoryandorseverejuveniledermatomyositis AT meipinglu shorttermeffectivenessofbaricitinibinchildrenwithrefractoryandorseverejuveniledermatomyositis AT jianqiangwu shorttermeffectivenessofbaricitinibinchildrenwithrefractoryandorseverejuveniledermatomyositis AT lixiazou shorttermeffectivenessofbaricitinibinchildrenwithrefractoryandorseverejuveniledermatomyositis AT yipingxu shorttermeffectivenessofbaricitinibinchildrenwithrefractoryandorseverejuveniledermatomyositis AT xuefengxu shorttermeffectivenessofbaricitinibinchildrenwithrefractoryandorseverejuveniledermatomyositis |